Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Cellular senescence associated immune responses in liver cancer.

Greten TF, Eggert T.

Hepat Oncol. 2017 Oct;4(4):123-127. doi: 10.2217/hep-2017-0011. Epub 2017 Nov 17. Review.

PMID:
29230285
2.

Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.

Pourebrahim R, Zhang Y, Liu B, Gao R, Xiong S, Lin PP, McArthur MJ, Ostrowski MC, Lozano G.

Genes Dev. 2017 Sep 15;31(18):1847-1857. doi: 10.1101/gad.304972.117. Epub 2017 Oct 11.

PMID:
29021240
3.

Blocking the utilization of glucose induces the switch from senescence to apoptosis in pseudolaric acid B-treated human lung cancer cells in vitro.

Yao GD, Yang J, Li XX, Song XY, Hayashi T, Tashiro SI, Onodera S, Song SJ, Ikejima T.

Acta Pharmacol Sin. 2017 Oct;38(10):1401-1411. doi: 10.1038/aps.2017.39. Epub 2017 Jun 26.

PMID:
28649131
4.

Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells.

Srdic-Rajic T, Santibañez JF, Kanjer K, Tisma-Miletic N, Cavic M, Galun D, Jevric M, Kardum N, Konic-Ristic A, Zoranovic T.

Sci Rep. 2017 Jun 19;7(1):3763. doi: 10.1038/s41598-017-03898-0.

5.

The imidazoacridinone C-1311 induces p53-dependent senescence or p53-independent apoptosis and sensitizes cancer cells to radiation.

Skwarska A, Ramachandran S, Dobrynin G, Leszczynska KB, Hammond EM.

Oncotarget. 2017 May 9;8(19):31187-31198. doi: 10.18632/oncotarget.16102.

6.

TNBC invasion: downstream of STAT3.

Jackson JG, Lozano G.

Oncotarget. 2017 Mar 28;8(13):20517-20518. doi: 10.18632/oncotarget.15259. No abstract available.

7.

IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay.

Weng J, Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang L, Yang J, Yi Q, Neelapu SS, Kwak LW.

Oncoimmunology. 2016 Oct 7;5(12):e1237327. doi: 10.1080/2162402X.2016.1237327. eCollection 2016.

8.

Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer.

Hatoum D, Yagoub D, Ahadi A, Nassif NT, McGowan EM.

PLoS One. 2017 Jan 9;12(1):e0169925. doi: 10.1371/journal.pone.0169925. eCollection 2017.

9.

Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.

Vogiatzi F, Brandt DT, Schneikert J, Fuchs J, Grikscheit K, Wanzel M, Pavlakis E, Charles JP, Timofeev O, Nist A, Mernberger M, Kantelhardt EJ, Siebolts U, Bartel F, Jacob R, Rath A, Moll R, Grosse R, Stiewe T.

Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8433-E8442. doi: 10.1073/pnas.1612711114. Epub 2016 Dec 12.

10.

Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy.

Benkafadar N, Menardo J, Bourien J, Nouvian R, François F, Decaudin D, Maiorano D, Puel JL, Wang J.

EMBO Mol Med. 2017 Jan;9(1):7-26. doi: 10.15252/emmm.201606230.

11.

TP53 drives invasion through expression of its Δ133p53β variant.

Gadea G, Arsic N, Fernandes K, Diot A, Joruiz SM, Abdallah S, Meuray V, Vinot S, Anguille C, Remenyi J, Khoury MP, Quinlan PR, Purdie CA, Jordan LB, Fuller-Pace FV, de Toledo M, Cren M, Thompson AM, Bourdon JC, Roux P.

Elife. 2016 Sep 15;5. pii: e14734. doi: 10.7554/eLife.14734.

12.

Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines.

Simova J, Sapega O, Imrichova T, Stepanek I, Kyjacova L, Mikyskova R, Indrova M, Bieblova J, Bubenik J, Bartek J, Hodny Z, Reinis M.

Oncotarget. 2016 Aug 23;7(34):54952-54964. doi: 10.18632/oncotarget.10712.

13.

Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.

Oweida A, Sharifi Z, Halabi H, Xu Y, Sabri S, Abdulkarim B.

Cancer Biol Ther. 2016 Apr 2;17(4):390-9. doi: 10.1080/15384047.2016.1139241.

14.

EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.

Smonskey M, Lasorsa E, Rosario S, Kirk JS, Hernandez-Ilizaliturri FJ, Ellis L.

Oncoscience. 2016 Jan 29;3(1):21-30. eCollection 2016.

15.

Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance.

Gibadulinova A, Pastorek M, Filipcik P, Radvak P, Csaderova L, Vojtesek B, Pastorekova S.

Oncotarget. 2016 Apr 19;7(16):22508-22. doi: 10.18632/oncotarget.7999.

16.

Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.

Pechackova S, Burdova K, Benada J, Kleiblova P, Jenikova G, Macurek L.

Oncotarget. 2016 Mar 22;7(12):14458-75. doi: 10.18632/oncotarget.7363.

17.

The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line.

Armat M, Oghabi Bakhshaiesh T, Sabzichi M, Shanehbandi D, Sharifi S, Molavi O, Mohammadian J, Saeid Hejazi M, Samadi N.

Bosn J Basic Med Sci. 2016 Jan 1;16(1):28-34. doi: 10.17305/bjbms.2016.674.

18.

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.

Iyer SV, Parrales A, Begani P, Narkar A, Adhikari AS, Martinez LA, Iwakuma T.

Oncotarget. 2016 Feb 2;7(5):5401-15. doi: 10.18632/oncotarget.6634.

19.

Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.

Yang MC, Lin RW, Huang SB, Huang SY, Chen WJ, Wang S, Hong YR, Wang C.

Cell Cycle. 2016;15(3):394-402. doi: 10.1080/15384101.2015.1127470.

20.

p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells.

Harajly M, Zalzali H, Nawaz Z, Ghayad SE, Ghamloush F, Basma H, Zainedin S, Rabeh W, Jabbour M, Tawil A, Badro DA, Evan GI, Saab R.

Mol Cell Biol. 2015 Nov 23;36(3):438-51. doi: 10.1128/MCB.00747-15.

Supplemental Content

Support Center